trimetrexate trimetrexate trimetrexate is a quinazoline derivative. it is a dihydrofolate reductase inhibitor. trimetrexateclinical dataahfs/drugs.comconsumer drug informationmedlineplusa694019atc codep01ax07 (who) pharmacokinetic databioavailabilityvd: 20-30 litersmetabolismoxidative o-demethylation, followed by conjugation with glucuronide or sulfateelimination half-life11 to 12 hoursidentifiers iupac name 5-methyl-6- quinazoline-2,4-diamine cas number52128-35-5 ypubchem cid5583iuphar/bps7613drugbankdb01157 ychemspider5381 yuniiupn4iti8t4keggd06238 ychemblchembl119 ycomptox dashboard (epa)dtxsid3023714 chemical and physical dataformulac19h23n5o3molar mass369.425 g·mol−13d model (jsmol)interactive image smiles n3c1c(c(c(cc1)cnc2cc(oc)c(oc)c(oc)c2)c)c(nc3n)n inchi inchi=1s/c19h23n5o3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22h,9h2,1-4h3,(h4,20,21,23,24) ykey:noypylrcidnjjb-uhfffaoysa-n y (verify) uses it has been used with leucovorin in treating pneumocystis pneumonia. it has been investigated for use in treating leiomyosarcoma. it is a methotrexate (mtx) analog that is active against transport-deficient mtx-resistant tumor cells that overcome the acquired and natural resistance to methotrexate. other uses include skin lymphoma.